NRx Pharmaceuticals, Inc.
NRXP
$2.27
-$0.02-0.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -109.56% | 73.23% | 9.41% | 40.86% | 57.70% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,131.49% | -206.43% | 55.79% | -76.82% | -202.48% |
| Change in Net Operating Assets | -103.55% | -94.70% | 640.25% | -8.30% | 261.49% |
| Cash from Operations | 34.27% | 49.47% | 67.20% | 39.71% | 61.63% |
| Capital Expenditure | -- | -- | -- | -- | 0.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 0.00% |
| Total Debt Issued | 2,535.67% | -- | -- | -- | -98.43% |
| Total Debt Repaid | -196.54% | 1.05% | 98.89% | -- | -- |
| Issuance of Common Stock | -- | -- | -43.66% | 0.20% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 269.80% | 236.84% | -49.93% | -84.48% | -111.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 95.29% | 95.85% | 137.67% | 7.67% | -338.61% |